<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605032</url>
  </required_header>
  <id_info>
    <org_study_id>11-12-434</org_study_id>
    <secondary_id>NCI-2013-01207</secondary_id>
    <secondary_id>11-102</secondary_id>
    <secondary_id>11-12-434</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01605032</nct_id>
  </id_info>
  <brief_title>Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line&#xD;
      stem cell transplant works in treating patients with multiple myeloma. Giving chemotherapy&#xD;
      before a peripheral blood stem cell transplant may stop the growth of cancer cells by&#xD;
      stopping them from dividing or killing them. After treatment, stem cells are collected from&#xD;
      the patient's blood and stored. The stem cells are then returned to the patient to replace&#xD;
      the blood-forming cells that were destroyed by the chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the complete response rate as defined by the International Myeloma Working&#xD;
      Group (IMWG) criteria for patients with multiple myeloma treated with high dose chemotherapy&#xD;
      with pharmacokinetic (PK) directed intravenous (IV) busulfan, bortezomib and melphalan&#xD;
      (Bu/BTZ/Mel140) followed by autologous hematopoietic stem cell transplantation (ASCT) as&#xD;
      first line therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate of the regimen Bu/BTZ/Mel140. II. To determine the&#xD;
      treatment related toxicity and mortality of the regimen, including 100-day mortality rates.&#xD;
&#xD;
      III. To determine the duration of response, time to progression, progression-free survival,&#xD;
      event-free survival and overall survival for this conditioning regimen.&#xD;
&#xD;
      IV. To determine whether there is a gender or race difference in the pharmacokinetic profile&#xD;
      of IV busulfan.&#xD;
&#xD;
      V. To determine methylation and gene expression signatures of pre-treatment bone marrow&#xD;
      plasma cells and explore associations of these signatures with outcome.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over&#xD;
      20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
&#xD;
      TRANSPLANT: Patients undergo autologous peripheral blood stem cell transplant (PBSCT) on day&#xD;
      0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Response as Determined by the IMWG Criteria</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of patients achieved complete response after the treatment regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression</measure>
    <time_frame>From start of treatment to disease progression with deaths, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The progression free survival was assessed over a period of 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The overall survival of patients was measured of a period of 2 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>DS Stage I Plasma Cell Myeloma</condition>
  <condition>DS Stage II Plasma Cell Myeloma</condition>
  <condition>DS Stage III Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSCT</description>
    <arm_group_label>Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSCT</description>
    <arm_group_label>Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed multiple myeloma&#xD;
&#xD;
          -  Measurable disease must be present as defined by protein criteria (quantifiable&#xD;
             M-component in serum, urine or serum free light chains) in order to evaluate response&#xD;
             as per IMWG; non-secretory patients are eligible provided the patient has &gt; 20%&#xD;
             plasmacytosis OR multiple (&gt; 3) focal plasmacytomas or focal lesions on magnetic&#xD;
             resonance imaging (MRI)&#xD;
&#xD;
          -  Patients must have received induction chemotherapy for myeloma, but not more than 12&#xD;
             months of prior chemotherapy for this disease, and must be eligible for the first&#xD;
             planned autologous transplant&#xD;
&#xD;
          -  A minimum stem cell dose of 2.0 x 10^6 cluster of differentiation 34-positive (CD34+)&#xD;
             cells/kg has been collected&#xD;
&#xD;
          -  Life expectancy of greater than 12 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL (unless myeloma related)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL (unless myeloma related)&#xD;
&#xD;
          -  Platelets &gt;= 50,000/mcL (unless myeloma related)&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 x institutional upper limit of normal unless 2nd to Gilbert's&#xD;
             disease&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 3 x institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x institutional upper limit of normal OR creatinine clearance &gt;= 60&#xD;
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
          -  Ejection fraction by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) &gt;=&#xD;
             40% performed within 60 days prior to registration&#xD;
&#xD;
          -  Patients must have adequate pulmonary function studies: &gt; 50% of predicted on&#xD;
             mechanical aspects (forced expiratory volume in one second [FEV1], forced vital&#xD;
             capacity [FVC]) and diffusion capacity (diffusing capacity of the lung for carbon&#xD;
             monoxide [DLCO]) &gt; 50% of predicted, within 60 days of registration; if the patients&#xD;
             is unable to complete pulmonary function tests due to multiple myeloma (MM) related&#xD;
             pain or condition, exception may be granted if the principal investigator (PI)&#xD;
             documents that the patient is a candidate for high dose therapy&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             at least six months following the stem cell transplantation; should a woman become&#xD;
             pregnant or suspect she is pregnant while participating in this study, she should&#xD;
             inform her treating physician immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering&#xD;
             the study or those who have not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks earlier&#xD;
&#xD;
          -  Prior treatment history of autologous hematopoietic stem cell transplant (HSCT) or&#xD;
             high-dose chemotherapy with stem cell rescue for any medical reason, not limited to&#xD;
             myeloma treatment&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with known brain metastases should be excluded from this clinical trial&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to or other agents used in the study, such as busulfan, melphalan,&#xD;
             bortezomib, boron, or mannitol&#xD;
&#xD;
          -  Grade 2 or greater peripheral neuropathy within 14 days prior to enrollment&#xD;
&#xD;
          -  Unresolved grade &gt;= 3 non-hematologic toxicity from previous therapy; patients with&#xD;
             grade 2 toxicity will be eligible at the discretion of the PI&#xD;
&#xD;
          -  Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma&#xD;
             in situ; cancer treated with curative intent &lt; 5 years will not be allowed unless&#xD;
             approved by the PI; cancer treated with curative intent &gt; 5 years will be allowed&#xD;
&#xD;
          -  Patients must not have significant co-morbid medical condition&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements; patients must not have suffered recent (&lt; 6 months) myocardial&#xD;
             infarction, unstable angina, difficult to control congestive heart failure,&#xD;
             uncontrolled hypertension, or difficult to control cardiac arrhythmias&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with busulfan&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
&#xD;
          -  Patients found to have an active hepatitis B infection (hepatitis B surface antigen +)&#xD;
             are not eligible unless they meet ONE of the following criteria:&#xD;
&#xD;
               -  Patient is able to start dual anti-hepatitis (Hep) B therapy prior to enrollment&#xD;
                  with adefovir and telbivudine&#xD;
&#xD;
               -  Patient is already on dual anti-hepatitis B therapy&#xD;
&#xD;
               -  Consultation and co-management with a hepatitis expert regarding hepatitis B&#xD;
                  treatment is strongly encouraged before and during the trial&#xD;
&#xD;
          -  Patients, who are positive for hepatitis B core antibody, but negative for the&#xD;
             hepatitis B surface antigen, should be started on lamivudine 100 mg daily until at&#xD;
             least 3 months post stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira Braunschweig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <results_first_submitted>March 17, 2020</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Ira Braunschweig</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT01605032/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT01605032/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
          <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
          <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="32" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ISS stage at diagnosis</title>
          <description>The international staging system (ISS) was used to stage the patients.&#xD;
Stage I: Serum beta-2 microglobulin &lt; 3.5 mg/L and serum albumin ≥3.5 g/dL - Good outcome&#xD;
Stage II: Not stage I or stage III - Slightly worse outcome&#xD;
Stage III: Serum beta-2 microglobulin ≥ 5.5 mg/L - Worse outcome&#xD;
For 16 of them ISS was available at initial diagnosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage unkown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytogenetics/FISH at diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standard risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bortezomib-containing regimen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunomodulatory agent-containing regimen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Response before ASCT</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Complete response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good partial response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Complete Response as Determined by the IMWG Criteria</title>
        <description>Number of patients achieved complete response after the treatment regimen</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
            <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Response as Determined by the IMWG Criteria</title>
          <description>Number of patients achieved complete response after the treatment regimen</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
            <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <time_frame>Up to day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
            <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-progression</title>
        <time_frame>From start of treatment to disease progression with deaths, up to 2 years</time_frame>
        <population>The outcome measure 'Time to Progression' was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
            <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-progression</title>
          <population>The outcome measure 'Time to Progression' was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>The progression free survival was assessed over a period of 2 years</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
            <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The progression free survival was assessed over a period of 2 years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The overall survival of patients was measured of a period of 2 years.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
            <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The overall survival of patients was measured of a period of 2 years.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)</title>
          <description>CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.&#xD;
TRANSPLANT: Patients undergo autologous PBSCT on day 0.&#xD;
Busulfan: Given IV&#xD;
Melphalan: Given IV&#xD;
Bortezomib: Given IV&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT&#xD;
Peripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death - 70 days after the autologous stem cell transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dysphagia/Odynophagia</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea and/or vomitting</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte abnormalities</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fever without neutropenia</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <description>Grade 3, 4 &amp; 5</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Noninfectious pulmonary toxicity</sub_title>
                <description>Grade 3 &amp; 4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ira Braunschweig, MD</name_or_title>
      <organization>Albert Einstein College of Medicine/Montefiore Medical Center</organization>
      <phone>718-920-4057</phone>
      <email>IBRAUNSC@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

